Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-04-07 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
年报披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is very short (290 characters) and is titled as a '2020 Annual Report Reminder Announcement'. It states that the 2020 Annual Report and summary have been disclosed on the official disclosure website and advises investors to review it. There is no actual financial data or detailed report content included, only a notice about the report's availability. According to the 'MENU VS MEAL' rule, this is an announcement about the report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2021-04-07 Chinese
关于获得药品生产申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug production application acceptance notice from the National Medical Products Administration. It details the product, its market and R&D background, and the cooperation agreement for production. The document is short (1175 characters) and serves as a formal notification of a regulatory acceptance rather than a financial report or detailed operational report. It does not contain financial data, management changes, voting results, or other report types. It is an official regulatory announcement about a drug production application acceptance, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-23 Chinese
国元证券股份有限公司关于安徽安科生物工程（集团）股份有限公司以参股公司股权向博生吉医药科技（苏州）有限公司增资暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed opinion and verification report from Guoyuan Securities Co., Ltd. regarding a related-party transaction involving Anhui Anke Biotechnology (Group) Co., Ltd. The transaction concerns capital increase by contribution of equity in an associate company to another company, with detailed descriptions of the transaction, parties involved, financial data, valuation reports, and legal and procedural compliance. The document includes audit reports from an accounting firm but is primarily a verification and opinion report by the sponsor institution on the related-party transaction. It is not a full annual or interim financial report, nor an earnings release or management discussion. It is not a proxy, voting result, or governance document. It is a regulatory announcement related to a capital transaction and related-party dealings, with detailed compliance and verification opinions. Given the nature of the document as a verification opinion on a capital increase and related-party transaction, it fits best under Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a substantive report on the transaction and its verification.
2021-03-05 Chinese
关于第七届董事会第八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution passed at the eighth meeting of the seventh board of directors of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the approval of a related-party transaction involving capital increase by equity contribution to a related company. The document includes voting results and mentions the independent directors' opinions. It is a formal announcement of board decisions and changes related to corporate governance and transactions, not a full report or financial statement. The document length is short (1169 characters), and it is clearly a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG).
2021-03-05 Chinese
关于第七届监事会第七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the seventh meeting of the seventh Supervisory Board of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the approval of a related-party transaction involving capital increase by equity transfer. The document includes meeting attendance, voting results, and references a related announcement on a regulatory disclosure website. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board/management decision related to corporate governance and transactions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or financial release.
2021-03-05 Chinese
关于以参股公司股权向博生吉医药科技（苏州）有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding an equity investment transaction involving its associate companies. It includes comprehensive information about the transaction, the companies involved, their financial data, the pricing policy, the agreement terms, and approvals from the board and independent directors. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a formal disclosure of a capital/financing update related to an equity investment and related party transaction. The presence of detailed transaction terms, financial data of the involved entities, and regulatory compliance statements aligns with the Capital/Financing Update category (CAP).
2021-03-05 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.